Ramkumar Iyer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ramkumar Iyer has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Alita A. Miller
Entasis Therapeutics, Waltham, Massachusetts, USA
6 shared publications - Ruben Tommasi
Entasis Therapeutics, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States
4 shared publications - Samir H. Moussa
Innoviva Specialty Therapeutics, Inc., an affiliate of Entasis Therapeutics Inc
4 shared publications - Andrew Camilli
Department of Molecular Biology and Microbiology, Graduate School of Biomedical Sciences, Tufts University School of Medicine, Boston, Massachusetts, USA
2 shared publications Annette Ferrari
Vertex Pharmaceuticals Incorporated , 50 Northern Avenue , Boston , Massachusetts 02210 , United States
2 shared publications- Adam B. Shapiro
Entasis Therapeutics, Gatehouse Park BioHub, Waltham, Massachusetts, USA
1 shared publication
Latest Publications
- Open Access
- 15 November 2023
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 67 (11) , e0066523
Molecular drivers of resistance to sulbactam-durlobactam in contemporary clinical isolates ofAcinetobacter baumannii
Acinetobacter baumannii-calcoaceticuscomplex (ABC) causes severe infections that are difficult to treat due to pre-existing antibiotic resistance. Sulbactam-durlobactam (SUL-DUR) is a targeted β-lactam/β-lactamase inhibitor combination antibiotic designed to treat serious infections caused byAcinetobacter, including multidrug- and carbapenem-resistant strains. In a recent global surveillance study of 5,032 ABC clinical isolates collected from 2016 to 2021, less than 2% of ABC isolates had SUL-DUR MIC values >4 µg/mL. Molecular characterization of these isolates confirmed the primary drivers of resistance are metallo-β-lactamases or penicillin-binding protein 3 (PBP3) mutations, as previously described. In addition, this study shows that certain common PBP3 variants, such as A515V, are insufficient to confer sulbactam resistance and that the efflux of durlobactam by AdeIJK is likely to play a role in a subset of strains.
- 15 November 2023
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 67 (11) , e0066523
Open AccessMolecular drivers of resistance to sulbactam-durlobactam in contemporary clinical isolates ofAcinetobacter baumannii
Acinetobacter baumannii-calcoaceticuscomplex (ABC) causes severe infections that are difficult to treat due to pre-existing antibiotic resistance. Sulbactam-durlobactam (SUL-DUR) is a targeted β-lactam/β-lactamase inhibitor combination antibiotic designed to treat serious infections caused byAcinetobacter, including multidrug- and carbapenem-resistant strains. In a recent global surveillance study of 5,032 ABC clinical isolates collected from 2016 to 2021, less than 2% of ABC isolates had SUL-DUR MIC values >4 µg/mL. Molecular characterization of these isolates confirmed the primary drivers of resistance are metallo-β-lactamases or penicillin-binding protein 3 (PBP3) mutations, as previously described. In addition, this study shows that certain common PBP3 variants, such as A515V, are insufficient to confer sulbactam resistance and that the efflux of durlobactam by AdeIJK is likely to play a role in a subset of strains.
- 22 September 2021
- Published by SAE International in SAE International Journal of Advances and Current Practices in Mobility
- Vol. 04 (3) , 806-812
Intelligent Adjustment of Free Play in Mechanically Operated Release System Achieved Digital
Agricultural Tractors consisting of a conventional manual transmission and dry friction clutch are mostly assembled with a mechanical type of clutch release mechanism where a defined amount of free play needs to be maintained between the clutch and Release Mechanism. A defined free play is required for efficient operation of clutch, Release Bearing as well as to ensure the durability of the system. As the clutch disc wears the free play between diaphragm spring or levers (as the case may be) and the release bearing is reduced. The rate at which the clutch disc wears is dependent on many factors like working condition of the tractor, grade of the friction lining material, experience of the driver, etc. This makes it very difficult to predict the exact timeline when the free play needs to be adjusted even though an approximate indication is given in instruction manuals. In today’s situation the adjustment of the free play is carried out manually and approximately. Many times, the adjustment activity is neglected, and this leads to early failures of the clutch release bearings and / or clutch. The purpose of this solution is to ensure that the free play adjustment is automatically carried out ensuring longer life of components. The system used for automation consists of a sensorized bearing, smart logic controller, and an actuator motor. As the adjustment would be carried out digitally, it would check and ensure the required free play is always available in the system, as well as eliminate manual intervention. The same can be extended to other areas of applications like commercial vehicles etc. where a mechanical release system is used. This paper describes the innovative ways to automatically maintain a fixed value of free play between the Diaphragm Spring fingers and the clutch release bearing at any point of time as well as to automate this process without manual intervention.
- 22 September 2021
- Published by SAE International in SAE International Journal of Advances and Current Practices in Mobility
- Vol. 04 (3) , 806-812
Intelligent Adjustment of Free Play in Mechanically Operated Release System Achieved Digital
Agricultural Tractors consisting of a conventional manual transmission and dry friction clutch are mostly assembled with a mechanical type of clutch release mechanism where a defined amount of free play needs to be maintained between the clutch and Release Mechanism. A defined free play is required for efficient operation of clutch, Release Bearing as well as to ensure the durability of the system. As the clutch disc wears the free play between diaphragm spring or levers (as the case may be) and the release bearing is reduced. The rate at which the clutch disc wears is dependent on many factors like working condition of the tractor, grade of the friction lining material, experience of the driver, etc. This makes it very difficult to predict the exact timeline when the free play needs to be adjusted even though an approximate indication is given in instruction manuals. In today’s situation the adjustment of the free play is carried out manually and approximately. Many times, the adjustment activity is neglected, and this leads to early failures of the clutch release bearings and / or clutch. The purpose of this solution is to ensure that the free play adjustment is automatically carried out ensuring longer life of components. The system used for automation consists of a sensorized bearing, smart logic controller, and an actuator motor. As the adjustment would be carried out digitally, it would check and ensure the required free play is always available in the system, as well as eliminate manual intervention. The same can be extended to other areas of applications like commercial vehicles etc. where a mechanical release system is used. This paper describes the innovative ways to automatically maintain a fixed value of free play between the Diaphragm Spring fingers and the clutch release bearing at any point of time as well as to automate this process without manual intervention.
- 1 March 2019
- Published by Elsevier in Research in Microbiology
- Vol. 170 (2) , 112-116
Role of the Klebsiella pneumoniae TolC porin in antibiotic efflux
- 1 March 2019
- Published by Elsevier in Research in Microbiology
- Vol. 170 (2) , 112-116
Role of the Klebsiella pneumoniae TolC porin in antibiotic efflux
- 29 November 2018
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 5 (1) , 49-54
Titrating Levels of TolC in E. coli: A Sensitive Approach to Quantifying Efflux
The susceptibility of small molecules to Gram-negative bacterial efflux is typically evaluated using an antibacterial activity-based efflux ratio, which is computed as the ratio of the antibacterial activity for a wild-type strain and its isogenic efflux mutant (typically lacking genes encoding major efflux pumps). The magnitude of the ratio is often used as an efflux index. However, early in drug discovery, hits with suboptimal physicochemical properties often lack whole cell inhibition against wild-type strains, which makes efflux ratios indeterminable. To address this gap, we developed an assay to titrate levels of total efflux by varying the TolC expression using an arabinose-inducible promoter (pBAD) in an Escherichia coli ΔtolC strain. We provide a proof of concept for the assay using sets of related compounds from two antibiotic classes and show that the TolC titration provides a sensitive method for rank ordering compounds with respect to their efflux susceptibility.
- 29 November 2018
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 5 (1) , 49-54
Titrating Levels of TolC in E. coli: A Sensitive Approach to Quantifying Efflux
The susceptibility of small molecules to Gram-negative bacterial efflux is typically evaluated using an antibacterial activity-based efflux ratio, which is computed as the ratio of the antibacterial activity for a wild-type strain and its isogenic efflux mutant (typically lacking genes encoding major efflux pumps). The magnitude of the ratio is often used as an efflux index. However, early in drug discovery, hits with suboptimal physicochemical properties often lack whole cell inhibition against wild-type strains, which makes efflux ratios indeterminable. To address this gap, we developed an assay to titrate levels of total efflux by varying the TolC expression using an arabinose-inducible promoter (pBAD) in an Escherichia coli ΔtolC strain. We provide a proof of concept for the assay using sets of related compounds from two antibiotic classes and show that the TolC titration provides a sensitive method for rank ordering compounds with respect to their efflux susceptibility.
- 30 June 2018
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 4 (9) , 1336-1345
Evaluating LC–MS/MS To Measure Accumulation of Compounds within Bacteria
A general method for determining bacterial uptake of compounds independent of antibacterial activity would be a valuable tool in antibacterial drug discovery. LC-MS/MS assays have been described, but it has not been shown whether the data can be used directly to inform medicinal chemistry. We describe the evaluation of an LC-MS/MS assay measuring association of compounds with bacteria, using a set of over a hundred compounds (inhibitors of NAD-dependent DNA ligase, LigA) for which in vitro potency and antibacterial activity had been determined. All compounds were active against an efflux-deficient strain of Escherichia coli with reduced LigA activity (E. coli ligA251 ΔtolC). Testing a single compound concentration and incubation time, we found that, for equipotent compounds, LC-MS/MS values were not predictive of antibacterial activity. This indicates that measured bacteria-associated compound was not necessarily exposed to the target enzyme. Our data suggest that, while exclusion from bacteria is a major reason for poor antibacterial activity of potent compounds, the distribution of compound within the bacterial cell may also be a problem. The relative importance of these factors is likely to vary from one chemical series to another. Our observations provide directions for further study of this difficult issue.
- 30 June 2018
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 4 (9) , 1336-1345
Evaluating LC–MS/MS To Measure Accumulation of Compounds within Bacteria
A general method for determining bacterial uptake of compounds independent of antibacterial activity would be a valuable tool in antibacterial drug discovery. LC-MS/MS assays have been described, but it has not been shown whether the data can be used directly to inform medicinal chemistry. We describe the evaluation of an LC-MS/MS assay measuring association of compounds with bacteria, using a set of over a hundred compounds (inhibitors of NAD-dependent DNA ligase, LigA) for which in vitro potency and antibacterial activity had been determined. All compounds were active against an efflux-deficient strain of Escherichia coli with reduced LigA activity (E. coli ligA251 ΔtolC). Testing a single compound concentration and incubation time, we found that, for equipotent compounds, LC-MS/MS values were not predictive of antibacterial activity. This indicates that measured bacteria-associated compound was not necessarily exposed to the target enzyme. Our data suggest that, while exclusion from bacteria is a major reason for poor antibacterial activity of potent compounds, the distribution of compound within the bacterial cell may also be a problem. The relative importance of these factors is likely to vary from one chemical series to another. Our observations provide directions for further study of this difficult issue.
- 27 February 2018
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 4 (5) , 686-695
Antibacterial Drug Discovery: Some Assembly Required
Our limited understanding of the molecular basis for compound entry into and efflux out of Gram-negative bacteria is now recognized as a key bottleneck for the rational discovery of novel antibacterial compounds. Traditional, large-scale biochemical or target-agnostic phenotypic antibacterial screening efforts have, as a result, not been very fruitful. A main driver of this knowledge gap has been the historical lack of predictive cellular assays, tools, and models that provide structure-activity relationships to inform optimization of compound accumulation. A variety of recent approaches have recently been described to address this conundrum. This perspective explores these approaches and considers ways in which their integration could successfully redirect antibacterial drug discovery efforts.
- 27 February 2018
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 4 (5) , 686-695
Antibacterial Drug Discovery: Some Assembly Required
Our limited understanding of the molecular basis for compound entry into and efflux out of Gram-negative bacteria is now recognized as a key bottleneck for the rational discovery of novel antibacterial compounds. Traditional, large-scale biochemical or target-agnostic phenotypic antibacterial screening efforts have, as a result, not been very fruitful. A main driver of this knowledge gap has been the historical lack of predictive cellular assays, tools, and models that provide structure-activity relationships to inform optimization of compound accumulation. A variety of recent approaches have recently been described to address this conundrum. This perspective explores these approaches and considers ways in which their integration could successfully redirect antibacterial drug discovery efforts.
- 20 December 2017
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 4 (3) , 373-381
Acinetobacter baumannii OmpA Is a Selective Antibiotic Permeant Porin
OmpAAb is a conserved, abundantly expressed outer membrane porin in Acinetobacter baumannii whose presumed role in antibiotic permeation has not been clearly demonstrated. In this report, we use a titratable heterologous expression system to express OmpAAb in isolation and demonstrate selective passage of small molecule antibiotics through OmpAAb. ETX2514, a recently discovered broad-spectrum β-lactamase inhibitor, in combination with sulbactam, is currently in clinical testing for the treatment of drug-resistant A. baumannii infections. We demonstrate that ETX2514 permeates OmpAAb and potentiates the activity of sulbactam in an OmpAAb-dependent manner. In addition, we show that small modifications in the structure of ETX2514 differentially affect its passage through OmpAAb, revealing unique structure-porin-permeation relationships. Finally, we confirm the contribution of OmpAAb to bacterial fitness using a murine thigh model of A. baumannii infection. These results, combined with the high sequence homology of OmpA across Acinetobacter spp., suggest that optimization of antibiotic entry through OmpAAb may prove to be a feasible medicinal chemistry design strategy for future antibacterial discovery efforts.
- 20 December 2017
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 4 (3) , 373-381
Acinetobacter baumannii OmpA Is a Selective Antibiotic Permeant Porin
OmpAAb is a conserved, abundantly expressed outer membrane porin in Acinetobacter baumannii whose presumed role in antibiotic permeation has not been clearly demonstrated. In this report, we use a titratable heterologous expression system to express OmpAAb in isolation and demonstrate selective passage of small molecule antibiotics through OmpAAb. ETX2514, a recently discovered broad-spectrum β-lactamase inhibitor, in combination with sulbactam, is currently in clinical testing for the treatment of drug-resistant A. baumannii infections. We demonstrate that ETX2514 permeates OmpAAb and potentiates the activity of sulbactam in an OmpAAb-dependent manner. In addition, we show that small modifications in the structure of ETX2514 differentially affect its passage through OmpAAb, revealing unique structure-porin-permeation relationships. Finally, we confirm the contribution of OmpAAb to bacterial fitness using a murine thigh model of A. baumannii infection. These results, combined with the high sequence homology of OmpA across Acinetobacter spp., suggest that optimization of antibiotic entry through OmpAAb may prove to be a feasible medicinal chemistry design strategy for future antibacterial discovery efforts.
- 17 February 2017
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 3 (4) , 310-319
Whole-Cell-Based Assay To Evaluate Structure Permeation Relationships for Carbapenem Passage through the Pseudomonas aeruginosa Porin OprD
The global emergence of antibiotic resistance, especially in Gram-negative bacteria, is an urgent threat to public health. Discovery of novel classes of antibiotics with activity against these pathogens has been impeded by a fundamental lack of understanding of the molecular drivers underlying small molecule uptake. Although it is well-known that outer membrane porins represent the main route of entry for small, hydrophilic molecules across the Gram-negative cell envelope, the structure–permeation relationship for porin passage has yet to be defined. To address this knowledge gap, we developed a sensitive and specific whole-cell approach in Escherichia coli called titrable outer membrane permeability assay system (TOMAS). We used TOMAS to characterize the structure porin–permeation relationships of a set of novel carbapenem analogues through the Pseudomonas aeruginosa porin OprD. Our results show that small structural modifications, especially the number and nature of charges and their position, have dramatic effects on the ability of these molecules to permeate cells through OprD. This is the first demonstration of a defined relationship between specific molecular changes in a substrate and permeation through an isolated porin. Understanding the molecular mechanisms that impact antibiotic transit through porins should provide valuable insights to antibacterial medicinal chemistry and may ultimately allow for the rational design of porin-mediated uptake of small molecules into Gram-negative bacteria.
- 17 February 2017
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 3 (4) , 310-319
Whole-Cell-Based Assay To Evaluate Structure Permeation Relationships for Carbapenem Passage through the Pseudomonas aeruginosa Porin OprD
The global emergence of antibiotic resistance, especially in Gram-negative bacteria, is an urgent threat to public health. Discovery of novel classes of antibiotics with activity against these pathogens has been impeded by a fundamental lack of understanding of the molecular drivers underlying small molecule uptake. Although it is well-known that outer membrane porins represent the main route of entry for small, hydrophilic molecules across the Gram-negative cell envelope, the structure–permeation relationship for porin passage has yet to be defined. To address this knowledge gap, we developed a sensitive and specific whole-cell approach in Escherichia coli called titrable outer membrane permeability assay system (TOMAS). We used TOMAS to characterize the structure porin–permeation relationships of a set of novel carbapenem analogues through the Pseudomonas aeruginosa porin OprD. Our results show that small structural modifications, especially the number and nature of charges and their position, have dramatic effects on the ability of these molecules to permeate cells through OprD. This is the first demonstration of a defined relationship between specific molecular changes in a substrate and permeation through an isolated porin. Understanding the molecular mechanisms that impact antibiotic transit through porins should provide valuable insights to antibacterial medicinal chemistry and may ultimately allow for the rational design of porin-mediated uptake of small molecules into Gram-negative bacteria.
- 1 July 2015
- Published by Elsevier in Research in Microbiology
- Vol. 166 (6) , 516-524
Direct measurement of efflux in Pseudomonas aeruginosa using an environment-sensitive fluorescent dye
- 1 July 2015
- Published by Elsevier in Research in Microbiology
- Vol. 166 (6) , 516-524
Direct measurement of efflux in Pseudomonas aeruginosa using an environment-sensitive fluorescent dye
- 1 April 2015
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 59 (4) , 2388-2397
A Fluorescent Microplate Assay Quantifies Bacterial Efflux and Demonstrates Two Distinct Compound Binding Sites in AcrB
A direct assay of efflux by Escherichia coli AcrAB-TolC and related multidrug pumps would have great value in discovery of new Gram-negative antibiotics. The current understanding of how efflux is affected by the chemical structure and physical properties of molecules is extremely limited, derived from antibacterial data for compounds that inhibit growth of wild-type E. coli . We adapted a previously described fluorescent efflux assay to a 96-well microplate format that measured the ability of test compounds to compete for efflux with Nile Red (an environment-sensitive fluor), independent of antibacterial activity. We show that Nile Red and the lipid-sensitive probe DiBAC 4 -(3) [bis-(1,3-dibutylbarbituric acid)-trimethine oxonol] can quantify efflux competition in E. coli . We extend the previous findings that the tetracyclines compete with Nile Red and show that DiBAC 4 -(3) competes with macrolides. The extent of the competition shows a modest correlation with the effect of the acrB deletion on MICs within the compound sets for both dyes. Crystallographic studies identified at least two substrate binding sites in AcrB, the proximal and distal pockets. High-molecular-mass substrates bound the proximal pocket, while low-mass substrates occupied the distal pocket. As DiBAC 4 -(3) competes with macrolides but not with Nile Red, we propose that DiBAC 4 -(3) binds the proximal pocket and Nile Red likely binds the distal site. In conclusion, competition with fluorescent probes can be used to study the efflux process for diverse chemical structures and may provide information as to the site of binding and, in some cases, enable rank-ordering a series of related compounds by efflux.
- 1 April 2015
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 59 (4) , 2388-2397
A Fluorescent Microplate Assay Quantifies Bacterial Efflux and Demonstrates Two Distinct Compound Binding Sites in AcrB
A direct assay of efflux by Escherichia coli AcrAB-TolC and related multidrug pumps would have great value in discovery of new Gram-negative antibiotics. The current understanding of how efflux is affected by the chemical structure and physical properties of molecules is extremely limited, derived from antibacterial data for compounds that inhibit growth of wild-type E. coli . We adapted a previously described fluorescent efflux assay to a 96-well microplate format that measured the ability of test compounds to compete for efflux with Nile Red (an environment-sensitive fluor), independent of antibacterial activity. We show that Nile Red and the lipid-sensitive probe DiBAC 4 -(3) [bis-(1,3-dibutylbarbituric acid)-trimethine oxonol] can quantify efflux competition in E. coli . We extend the previous findings that the tetracyclines compete with Nile Red and show that DiBAC 4 -(3) competes with macrolides. The extent of the competition shows a modest correlation with the effect of the acrB deletion on MICs within the compound sets for both dyes. Crystallographic studies identified at least two substrate binding sites in AcrB, the proximal and distal pockets. High-molecular-mass substrates bound the proximal pocket, while low-mass substrates occupied the distal pocket. As DiBAC 4 -(3) competes with macrolides but not with Nile Red, we propose that DiBAC 4 -(3) binds the proximal pocket and Nile Red likely binds the distal site. In conclusion, competition with fluorescent probes can be used to study the efflux process for diverse chemical structures and may provide information as to the site of binding and, in some cases, enable rank-ordering a series of related compounds by efflux.